Our API - USA Portfolio** consists of the following:
Therapeutic Category Name of API Regulatory Status
Anti-cancer Afatinib dimaleate *
Belinostat *
Busulfan *
Carfilzomib *
Decitabine *
Docetaxe anhydrous *
Gemcitabine HCl
Ibrutinib *
Paclitaxel Semi-synthetic
Ribociclib Succinate *
Alectinib HCl *
Plerixafor *
Reversal of neuromuscular blockade Sugammadex Sodium *
Anesthetics Bupivacaine Hydrochloride @
Ropivacaine Hydrochloride Monohydrate *
Ropivacaine Hydrochloride Anhydrous *
Antibiotic Chloramphenicol Hemisuccinate @

Granted   *Filed   @ To be filed – Not filed

**The buyer / customer should make their independent evaluation of the patent scenario for their respective markets, in respect of the API/formulations bought from Fresenius Kabi Oncology Limited, and they shall be solely and exclusively responsible for all patent related liabilities including any litigation by third party.

Fresenius Kabi Oncology Ltd. do not intend to manufacture any product commercially until there is a valid IP. Listing of product shall not be construed in any way that Fresenius Kabi Oncology has violated any IP laws of the land.


© All Copyright Reserved | Fresenius Kabi Oncology Limited 2012-2018